GENELUX Corp
GNLXGenelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity.
Drugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 6, 2026
6wMarket Overview
Stock performance and key metrics
2 upcoming, 1 past
olvimulogene nanivacirepvec
Platinum-resistant Ovarian Cancer
GL-ONC1
Peritoneal Carcinomatosis
Platinum chemotherapy: carboplatin or cisplatin
Advanced Non-squamous Non-small-cell Lung Cancer
Olvi-Vec
Ovarian Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
olvimulogene nanivacirepvec | Phase 3 | Platinum-resistant Ovarian Cancer | - | - |
GL-ONC1 | Phase 2 | Peritoneal Carcinomatosis | - | - |
Platinum chemotherapy: carboplatin or cisplatin | Phase 2 | Advanced Non-squamous Non-small-cell Lung Cancer | - | - |
Olvi-Vec | Phase 2 | Ovarian Cancer | - | - |